Telithromycin versus clarithromycin for the treatment of community-acquired respiratory tract infections: A meta-analysis of randomized controlled trials

Chinese Medical Journal

Volumn 126, Issue 11, 2013, Pages 2179-2185

  Li, Xiu Min ^a   Wang, Feng Chun ^a   Yang, Feng ^a   Jin, Ying Hua ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Clarithromycin; Community acquired respiratory tract infections; Meta analysis; Telithromycin

Indexed keywords

CLARITHROMYCIN; TELITHROMYCIN;

ABDOMINAL PAIN; ALLERGIC REACTION; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DATA EXTRACTION; DEATH; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; FATIGUE; FLATULENCE; HEADACHE; HUMAN; INFLUENZA; LIVER FUNCTION TEST; META ANALYSIS; MORAXELLA CATARRHALIS; NAUSEA; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE; SWELLING; SYSTEMATIC REVIEW; THORAX PAIN; THRUSH; TONSILLITIS; TREATMENT OUTCOME; VOMITING;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; KETOLIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS;

EID: 84878682700     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20122745     Document Type: Article

References (37)

1. File TM Jr. Overview of community-acquired respiratory tract infections. In: Nightingale CH, Ambrose PG, File TM Jr, eds. Community-Acquired Respiratory Infections: Antimicrobial Management. 3rd ed. New York: Marcel Dekker. 2005; 1-26.
2. Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31:347-382.
3. Gwaltney JM. Pharyngitis. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Disease. 3rd ed. New York: Churchill Livingstone. 1990; 493-498.
4. Ball P, Make B. Acute exacerbations of chronic bronchitis: an international comparison. Chest 1998; 113:199-204.
5. Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin-and erythromycin-susceptible and-resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998; 42: 624-630.
6. Felmingham D. Evolving resistance patterns in community-acquired respiratory tract pathogens: First results from the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin (PROTEKT) global surveillance study. J Infect 2002; 44: 3-10.
7. Baquero E. Evolving resistance patterns of Streptococnts pneumoniae: A link with long-acting macrolide consumption? J Chemother 1999; 11: 35-43.
8. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemoth 2002; 50 (Suppl S1): 25-37.
9. Balfour JA, Figgitt DP. Telithromycin. Drugs 2001; 61: 815-829.
10. Bebear CM, Renaudin H, Bryskier A, Bebear C. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother 2000; 44: 1980-1982.
11. Davies TA, Kelly LM, Jacobs MR, Appelbaum PC. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies. J Clin Microbiol 2000; 38: 1444-1448.
12. Quinn J, Ruoff GE, Ziter PS. Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study. Clin Ther 2003; 25: 422-443.
13. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004; 54: 515-523.
14. Mathers Dunbar L, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004; 26: 48-62.
15. Fogarty C, de Wet R, Mandell L, Chang J, Rangaraju M, Nusrat R. Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization. Chest 2005; 128: 1980-1988.
16. Perronne C, Drugeon H, Zuck P, Filipecki J, Vincent-Lacaze N, Goldfarb G, et al. Efficacy and safety of extended-release clarithromycin (5-day short-course) vs. telithromycin, in acute bacterial exacerbation of chronic bronchitis. Med Mal Infect 2005; 35: 507-515.
17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
18. Khan KS, Daya S, Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996; 156: 661-666.
19. Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care 1996; 12: 195-208.
20. Barry AL, Fuchs PC, Brown SD. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin). Antimicrob Agents Chemother 1998; 42: 945-946.
21. Roblin PM, Hammerschlag MR. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998; 42: 1515-1516.
22. Carbon C, Poole MD. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. J Chemother 1999; 11: 107-118.
23. Wierzbowski AK, Hoban DJ, Hisanaga T, DeCorby M, Zhanel GG. The use of macrolides in treatment of upper respiratory tract infections. Curr Allergy Asthma Rep 2006; 6: 171-181.
24. Saginur R. Barriers to the effective management of respiratory tract infections in the community. Infection 2001; 29: 3-10.
25. Ball P, Baquero F, Cars O, File T, Garau J, Klugman K, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49: 31-40.
26. File TM. The science of selecting antimicrobials for community-acquired pneumonia (CAP). J Manag Care Pharm 2009; 15: S5-S11.
27. File TM. Community-acquired pneumonia. Lancet 2003; 362: 1991-2001.
28. Siempos II, Michalopoulos A, Falagas ME. Treatment of acute bacterial exacerbations of chronic bronchitis. Expert Opin Pharmacother 2009; 10: 1173-1182.
29. Hansen LH, Mauvais P, Douthwaite S. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 1999; 31: 623-631.
30. Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44: 414-417.
31. Bonnefoy A, Girard AM, Agouridas C, Chantot JF. Ketolides lack inducibility properties of MLS(B) resistance phenotype. J Antimicrob Chemother 1997; 40: 85-90.
32. Edelstein PH, Edelstein MA. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 1999; 43: 90-95.
33. Schülin T, Wennersten CB, Ferraro MJ, Moellering RC Jr, Eliopoulos GM. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998; 42: 1520-1523.
34. Niederman MS, Chang JR, Stewart J, Nusrat R, Nieman RB. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin. Curr Med Res Opin 2004; 20: 749-756.
35. Niederman MS, Chang JR, Stewart J, Asche CV, Lavin B, Nusrat R, et al. Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials. Curr Med Res Opin 2004; 20: 969-980.
36. Lau J, Ioannidis JPA, Schmid CH. Summing up the evidence: one answer is not always enough. Lancet 1997; 351: 123-127.
37. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994; 309: 1351-1355.